Arch Biopartners is developing next-generation drug candidates that target IL-32, a cytokine implicated in diabetic kidney disease as described in Dr. Chun’s new publication. The goal is to produce a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results